• In early May 2026, Arcutis Biotherapeutics reported first-quarter 2026 results showing revenue of US$105.4 million versus US$65.85 million a year earlier, with net loss narrowing to US$11.3 million and basic loss per share improving to US$0.09, while reaffirming full-year 2026 net product revenue guidance of US$480 million to US$495 million.
• Alongside these results, Arcutis advanced ZORYVE’s label expansion by filing an FDA supplemental New Drug Application to treat mild to moderate atopic dermatitis in infants as young as 3 months, further underscoring its focus on non-steroidal options for very young patients who currently have few approved treatments.
• We’ll now examine how the reaffirmed 2026 revenue guidance and ZORYVE’s push into infant atopic dermatitis reshape Arcutis Biotherapeutics’ investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.

Arcutis Biotherapeutics Investment Narrative Recap

To own Arcutis, you really have to believe that ZORYVE can sustain and broaden its role in non steroidal dermatology while the company keeps moving closer to consistent profitability. The reaffirmed 2026 revenue guidance, alongside narrowing losses, supports that near term commercialization story, while the key risk remains the company’s concentration in the ZORYVE franchise if uptake slows or competition intensifies.

The recent sNDA filing to extend ZORYVE 0.05% to infants as young as 3 months is especially relevant here, because it directly targets a population with very limited approved non steroidal options and ties into Arcutis’ broader effort to expand ZORYVE across age groups and indications, which is central to both its main catalyst and its concentration risk.

Yet even as management leans into ZORYVE’s growth potential, investors should be aware that...

Arcutis Biotherapeutics’ narrative projects $784.6 million revenue and $266.1 million earnings by 2029.

Uncover how Arcutis Biotherapeutics' forecasts yield a $34.75 fair value, a 68% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$34.75 to US$81.45 per share, showing just how far apart individual views can be. Against that backdrop, the company’s reaffirmed 2026 revenue guidance and dependence on the ZORYVE franchise give you a concrete focal point for thinking about how those different expectations might play out in Arcutis’ actual results.

Explore 3 other fair value estimates on Arcutis Biotherapeutics - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arcutis Biotherapeutics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arcutis Biotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcutis Biotherapeutics' overall financial health at a glance.

No Opportunity In Arcutis Biotherapeutics?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.